82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody Favorable emerging safety and